Current Trends in Hepatocellular Carcinoma Therapies in China

Ying Zhang; Yong Wang; Jin-He Guo; Jian Lu

doi:10.1055/s-0044-1788691

Digestive Disease Interventions, Table of Contents

Digestive Disease Interventions 2024; 08(03): 173-182
DOI: 10.1055/s-0044-1788691

Review Article

Current Trends in Hepatocellular Carcinoma Therapies in China

Ying Zhang^*

¹Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China

²Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China

,

Yong Wang^*

¹Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China

²Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China

,

Jin-He Guo

¹Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China

²Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China

,

Jian Lu

¹Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China

²Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China

› Author Affiliations

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor that is particularly prevalent in China, making up almost 50% of HCC cases worldwide. Compared to HCC patients in Europe, North America, and the Asia-Pacific region, Chinese patients exhibit unique characteristics in etiology, demographics (age, gender, geographic location, economic status), biological behavior, treatment options, and prognosis. While hepatitis B virus remains a primary cause of HCC in China, there is a growing trend of alcoholic liver disease and nonalcoholic fatty liver disease in the country. A special pathological staging guidance distribution of therapies for HCC was developed by the Chinese Medical Association. In China, there is a diverse array of therapeutic options for treating HCC, including liver resection, liver transplantation, intra-arterial therapies, ablation, radiotherapies, systemic therapies, and traditional Chinese medicine. The treatment of HCC has multiple permutations and combinations of modalities. Due to the varying stages of HCC and individual patient differences, the multidisciplinary team model is often necessary to tailor treatment strategies and optimize clinical outcomes. Meanwhile, to enhance survival benefits and effectively improve the prognosis and life quality of patients with HCC, Chinese experts are actively engaged in conducting clinical trials to identify potential beneficiary populations. This review aims to elaborate on the therapeutic features of HCC in China to present to the world the innovative approaches and comprehensive care offered to Chinese HCC patients.

Keywords

hepatocellular carcinoma - therapies - multidisciplinary team

Full Text

References

References
1 Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol 2023; 20 (12) 864-884
2 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71 (01) 7-33
3 Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020; 40 (05) 205-210
4 Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012; 62 (06) 394-399
5 Zhou J, Sun H, Wang Z. et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer 2023; 12 (05) 405-444
6 Qi J, Li M, Wang L. et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health 2023; 8 (12) e943-e955
7 Arnold M, Abnet CC, Neale RE. et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020; 159 (01) 335-349.e15
8 Chen W, Sun K, Zheng R. et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res 2018; 30 (01) 1-12
9 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; Accessed July 12, 2024 at: https://gco.iarc.who.int/today Published online 2024
10 International Agency for Research on Cancer. Accessed July 12, 2024 at: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf Published online 2020
11 Chen W, Zheng R, Baade PD. et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66 (02) 115-132
12 Zhou M, Wang H, Zeng X. et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019; 394 (10204): 1145-1158
13 Guidelines of Chinese Society of Clinical Oncology(CSCO). Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). People's Medical Publishing House. Published online 2022:11–157
14 Zeng H, Chen W, Zheng R. et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health 2018; 6 (05) e555-e567
15 Allemani C, Weir HK, Carreira H. et al; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385 (9972): 977-1010
16 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65 (02) 87-108
17 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
18 Chen LT, Martinelli E, Cheng AL. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol 2020; 31 (03) 334-351
19 Chen T, Liu J, Li Y, Wei S. Burden of disease associated with dietary exposure to aflatoxins in China in 2020. Nutrients 2022; 14 (05) 1027
20 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021; 398 (10308): 1359-1376
21 Tan DJH, Setiawan VW, Ng CH. et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology 2023; 77 (04) 1150-1163
22 Huang DQ, Tan DJH, Ng CH. et al. Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2023; 21 (05) 1169-1177
23 Tan DJH, Ng CH, Lin SY. et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol 2022; 23 (04) 521-530
24 He J, Chen W, Shen H. et al. China guideline for liver cancer screening (2022, Beijing). Zhonghua Xiaohua Waike Zazhi 2022; 44 (08) 779-814
25 Zhou J, Sun HC, Wang Z. et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer 2018; 7 (03) 235-260
26 Yau T, Tang VYF, Yao TJ, Fan ST, Lo CM, Poon RTP. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146 (07) 1691-700.e3
27 Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 2018; 25 (04) 845-847
28 National Health Commission of the People's, Republic of China. Guidelines for the diagnosis and treatment of primary hepatic carcinoma (2022 edition). Journal of Multidisciplinary Cancer Management 2022; 8 (02) 16-53 (Electronic Version)
29 Yin L, Li H, Li AJ. et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol 2014; 61 (01) 82-88
30 Zhong JH, Ke Y, Gong W-F. et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg 2014; 260 (02) 329-340
31 Chinese Association of Liver Cancer of Chinese Medical Doctor Association. Chinese expert consensus on the diagnosis and treatment of hepatocellular carcinoma with microvascular invasion (2024 edition). Zhonghua Xiaohua Waike Zazhi 2024; 23 (02) 153-164
32 Bai S, Yang P, Xie Z. et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis B virus-related hepatocellular carcinoma. Ann Surg Oncol 2021; 28 (13) 8174-8185
33 Committee of Liver Surgeons, Chinese Congress of Surgeons, Chinese Medical Doctor Association. Chinese expert consensus on the application of indocyanine green near-infrared imaging technology in liver surgery (2023 edition). Chin J Pra Surg 2023; 43 (04) 371-383
34 Chinese Society of Digital Medicine. Chinese Medical Association, Liver Cancer Committee of Chinese Medical Doctor Association, Chinese Society of Minimally Invasive Surgery, Chinese College of Surgeons, Chinese Medical Doctor Association, Digital Intelligent Surgery Committee of Chinese Research Hospital Association. Chinese expert consensus on hepatectomy navigated by indocyanine green fluorescence combined with digital intelligent (version 2021). Chin J Pra Surg 2022; 42 (03) 274-284
35 Chinese Association of Liver Cancer of Chinese Medical Doctor Association. Chinese guidelines for the diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2021 edition). Zhonghua Yi Xue Za Zhi 2022; 102 (04) 243-254
36 Alliance of Chinese Expert Consensus on Neoadjuvant Therapy for Hepatocellular Carcinoma, Committee of Digestive Surgery of Chinese Research Hospital Association, Committee of Liver Cancer, Chinese Anti-Cancer Association. [Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition)]. Zhonghua Wai Ke Za Zhi 2023; 61 (12) 1035-1045
37 Zhu X, Jian Z. Consensus and controversies of neoadjuvant therapy for primary liver cancer. Chin J Pra Surg. 2023; 43 (04) 286-290 , 309
38 Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma, Chinese College of Surgeons, Committee of Liver Cancer, Chinese Anti-Cancer Association, Liver Cancer Group, Society of Oncology, Chinese Medical Association. Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma (2023 edition). Zhonghua Xiaohua Waike Zazhi 2023; 22 (04) 437-448
39 Zheng S, Shu L, Xu X. Chinese College of Transplant Doctors LTG, Chinese Society of Organ Transplantation CMA. Chinese clinical practice guidelines on liver transplantation for hepatocellular carcinoma (2021 edition). Zhonghua Xiaohua Waike Zazhi 2023; 21 (04) 433-443
40 Xu X, Lu D, Ling Q. et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut 2016; 65 (06) 1035-1041
41 Park JW, Chen M, Colombo M. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35 (09) 2155-2166
42 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocellular carcinoma before transplantation. Transplant Rev (Orlando) 2021; 35 (02) 100606
43 Shi GM, Wang J, Huang XW. et al. Graft programmed death ligand 1 expression as a marker for transplant rejection following anti-programmed death 1 immunotherapy for recurrent liver tumors. Liver Transpl 2021; 27 (03) 444-449
44 Nordness MF, Hamel S, Godfrey CM. et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. Am J Transplant 2020; 20 (03) 879-883
45 Chen J, Shen T, Li J. et al. Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition). Chin Med J (Engl) 2022; 135 (24) 2911-2913
46 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
47 Xu X, Pu X, Jiang L. et al. Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with multifocal tumours meeting the University of California San Francisco (UCSF) criteria. J Cancer Res Clin Oncol 2021; 147 (02) 607-618
48 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
49 Qu LS, Liu JX, Zhu J, Lu CH. Risk factors for prognosis of hepatocellular carcinoma after curative resection in patients with low hepatitis B viral load. Ann Hepatol 2017; 16 (03) 412-420
50 Xu X, Yang J, Zhong L. et al. The clinical value of “Hangzhou Criteria” in the selection of patients with hepatocellular carcinoma for liver transplantation: a report of l 163 cases on a multi-center basis. Chin J Organ Transplant. 2013; 34 (09) 524-527
51 Audet M, Panaro F, Piardi T, Wolf P. Are the Hangzhou criteria adaptable to hepatocellular carcinoma patients for liver transplantation in Western countries?. Liver Transpl 2009; 15 (07) 822-823 , author reply 824–826
52 Lu J, Zhao M, Arai Y. et al; International Society of Multidisciplinary Interventional Oncology (ISMIO). Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg Nutr 2021; 10 (05) 661-671
53 Ikeda M, Kudo M, Aikata H. et al; Miriplatin TACE Study Group. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol 2018; 53 (02) 281-290
54 Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016; 64 (01) 106-116
55 Teng G, Liu R, Zhu H. et al; Clinical Guidelines Committee of Chinese College of Interventionalists. [Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)]. Zhonghua Yi Xue Za Zhi 2023; 103 (34) 2674-2694
56 Zhou W, Yuan S. Research advances in conversion therapy for hepatocellular carcinoma. Zhonghua Xiaohua Waike Zazhi 2020; 19 (02) 130-134
57 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL clinical practice guidelines: liver transplantation. J Hepatol 2016; 64 (02) 433-485
58 Zhu K, Chen J, Lai L. et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib – a retrospective controlled study. Radiology 2014; 272 (01) 284-293
59 Lu J, Zhang XP, Zhong BY. et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol 2019; 4 (09) 721-730
60 Chung GE, Lee JH, Kim HY. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258 (02) 627-634
61 Silva JP, Berger NG, Tsai S. et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford) 2017; 19 (08) 659-666
62 Guo Z, Teng G, Zou Y. et al. Transarterial treatment of primary and secondary liver cancer with drug-eluting beads transarterial chemoembolization:technical recommendations. Zhonghua Fang She Xue Za Zhi 2019; 53 (05) 336-340
63 Chinese Society of Liver Cancer, China Anti-Cancer Association. Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma (2021 edition). Zhonghua Xiaohua Waike Zazhi 2021; 20 (07) 754-759
64 Kudo M, Matsui O, Izumi N. et al; Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer 2014; 3 (3-4): 458-468
65 Zhao M, Guo Z, Zou YH. et al. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatol Int 2024; 18 (01) 4-31
66 Lyu N, Kong Y, Mu L. et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol 2018; 69 (01) 60-69
67 Lyu N, Lin Y, Kong Y. et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut 2018; 67 (02) 395-396
68 He MK, Le Y, Li QJ. et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer 2017; 36 (01) 83
69 Lyu N, Wang X, Li JB. et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol 2022; 40 (05) 468-480
70 He M, Li Q, Zou R. et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol 2019; 5 (07) 953-960
71 Li SH, Mei J, Cheng Y. et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study. J Clin Oncol 2023; 41 (10) 1898-1908
72 Writing Group of Chinese Society of Interventional Radiology. Technical standards of transcatheter arterial chemoembolization for hepatocellular carcinoma: experts common opinion. Zhonghua Fang She Xue Za Zhi 2011; 45 (10) 908-912
73 Zhao D, Zhang L, Jiang X, Shi Y, Yan Z, Ni C. Is HAIC an obsolete technology or a novel therapeutic method? HAIC should be treated rationally. J Intervent Radiol 2022; 31 (01) 2-8
74 Song L, Zou Y. Experts consensus on management of yttrium 90 microspheres. Zhongguo Jieru Yingxiang Yu Zhiliaoxue 2021; 18 (06) 321-325
75 National Medical Products Administration. Yttrium [90Y] microsphere injection. 2022 Drug Review Report. September 06, 2023. Regulatory documentation FGWJ-2023-10001
76 Liu DM, Leung TW, Chow PK. et al. Clinical consensus statement: selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. Int J Surg 2022; 102: 106094
77 Chinese Medical Doctor Association, Clinical Guidelines Committee of Chinese College of Interventionalists, Chinese Research Hospital Association, Society for Hepato–pancreato–biliary Surgery. [Expert consensus on the standardized procedure of selective internal radiation therapy with yttrium-90 microspheres for liver malignancies (2024 edition)]. Zhonghua Yi Xue Za Zhi 2024; 104 (07) 486-498
78 Peng ZW, Zhang YJ, Chen MS. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31 (04) 426-432
79 Vitale A, Cabibbo G, Iavarone M. et al; HCC Special Interest Group of the Italian Association for the Study of the Liver. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol 2023; 24 (07) e312-e322
80 Committee of Minimally Invasive Therapy in Oncology, Chinese Anti-Cancer Association, Committee of Ablation Therapy in Oncology, Chinese Anti-Cancer Association.. Chinese expert consensus on co-ablation system for the treatment of primary liver cancer (2023 edition). J Intervent Radiol 2023; 32 (10) 949-953
81 Luo J, Dong Z, Xie H. et al. Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: a prospective multicenter study. Liver Int 2022; 42 (04) 918-929
82 Wang C, Wang H, Yang W. et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 2015; 61 (05) 1579-1590
83 Liang SX, Zhu XD, Xu ZY. et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006; 65 (02) 426-434
84 Wang W, Zeng Z. Chinese radiotherapy guidelines for primary hepatocellular carcinoma (2020 edition). J Clin Hepatol. 2021; 37 (05) 1029-1033
85 Wei X, Jiang Y, Zhang X. et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol 2019; 37 (24) 2141-2151
86 Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review. Hepatobiliary Pancreat Dis Int 2022; 21 (02) 134-144
87 Yamakado K, Nakatsuka A, Tanaka N, Fujii A, Terada N, Takeda K. Malignant portal venous obstructions treated by stent placement: significant factors affecting patency. J Vasc Interv Radiol 2001; 12 (12) 1407-1415
88 Lu J, Zhong BY, Zhu HD, Guo JH, Teng GJ. Embolotherapy of unresectable hepatocellular carcinoma: Eastern perspective. Chin Clin Oncol 2019; 8 (06) 60-60
89 Park HC, Yu JI, Cheng JCH. et al. Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): current practice and future clinical trials. Liver Cancer 2016; 5 (03) 162-174
90 Zhang ZH, Zhang W, Gu JY. et al. Treatment of hepatocellular carcinoma with tumor thrombus with the use of iodine-125 seed strand implantation and transarterial chemoembolization: a propensity-score analysis. J Vasc Interv Radiol 2018; 29 (08) 1085-1093
91 Lu J, Guo JH, Zhu HD, Zhu GY, Chen L, Teng GJ. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma: a single-center experience. J Vasc Interv Radiol 2017; 28 (06) 786-794.e3
92 Meng MB, Cui YL, Lu Y. et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009; 92 (02) 184-194
93 Lu J, Guo JH, Ji JS. et al. Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial. Int J Surg 2023; 109 (05) 1188-1198
94 Yang M, Fang Z, Yan Z. et al. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol 2014; 140 (02) 211-219
95 Luo JJ, Zhang ZH, Liu QX, Zhang W, Wang JH, Yan ZP. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus. Hepatol Int 2016; 10 (01) 185-195
96 The Chinese Chapter of the International Hepato-Pancreato-Biliary Association, Group of Liver Surgery, Surgical Society of Chinese Medical Association, Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology. Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma (2023 version). Zhonghua Xiaohua Waike Zazhi 2023; 22 (03) 293-315
97 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
98 Qin S, Chen M, Cheng AL. et al; IMbrave050 Investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402 (10415): 1835-1847
99 Ren Z, Xu J, Bai Y. et al; ORIENT-32 Study Group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021; 22 (07) 977-990
100 Qin S, Chan SL, Gu S. et al; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023; 402 (10408): 1133-1146
101 Xu J, Shen J, Gu S. et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res 2021; 27 (04) 1003-1011
102 Abou-Alfa GK, Lau G, Kudo M. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1 (08) a2100070
103 Chan SL, Kudo M, Sangro B. et al. 83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Ann Oncol 2022; 33: S1465-S1466
104 Chan SL, Kudo M, Sangro B. et al. 67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Ann Oncol 2022; 33: S1456
105 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34
106 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391 (10126): 1163-1173
107 Finn RS, Ikeda M, Zhu AX. et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020; 38 (26) 2960-2970
108 Llovet JM, Kudo M, Merle P. et al; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24 (12) 1399-1410
109 Keam SJ, Duggan S. Donafenib: first approval. Drugs 2021; 81 (16) 1915-1920
110 Qin S, Bi F, Gu S. et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol 2021; 39 (27) 3002-3011
111 Qin S, Kudo M, Meyer T. et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol 2023; 9 (12) 1651-1659
112 Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology(CSCO): Immune Checkpoint Inhibitor Clinical Practice(2023 Edition). 1st ed.. People's Medical Publishing House; 2023
113 Bruix J, Qin S, Merle P. et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10064): 56-66
114 Li BK, Yuan Y, Qiao L. et al. 949P Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter real-world study. Ann Oncol 2023; 34: S596
115 Qin S, Li Q, Gu S. et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2021; 6 (07) 559-568
116 Qin S, Ren Z, Meng Z. et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020; 21 (04) 571-580
117 Ren Z, Qin S, Meng Z. et al. A Phase 2 study of camrelizumab for advanced hepatocellular carcinoma: two-year outcomes and continued treatment beyond first RECIST-Defined Progression. Liver Cancer 2021; 10 (05) 500-509
118 Chen Q, Shu C, Laurence AD. et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut 2018; 67 (11) 2006-2016
119 Zhai XF, Liu XL, Shen F, Fan J, Ling CQ. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: a randomized controlled study. Cancer 2018; 124 (10) 2161-2168
120 Chang TT, Sawhney R, Monto A. et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford) 2008; 10 (06) 405-411